X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (318) 318
Publication (55) 55
Conference Proceeding (3) 3
Book / eBook (2) 2
Book Chapter (2) 2
Book Review (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (154) 154
hematology (126) 126
index medicus (119) 119
male (114) 114
middle aged (108) 108
female (107) 107
adult (97) 97
aged (92) 92
rituximab (66) 66
treatment outcome (57) 57
oncology (52) 52
antineoplastic combined chemotherapy protocols - therapeutic use (44) 44
aged, 80 and over (38) 38
non-hodgkins-lymphoma (31) 31
retrospective studies (31) 31
therapy (31) 31
disease-free survival (30) 30
prognosis (30) 30
adolescent (28) 28
chemotherapy (26) 26
survival (24) 24
lymphomas (23) 23
antibodies, monoclonal, murine-derived (22) 22
remission induction (22) 22
survival analysis (22) 22
abridged index medicus (21) 21
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
antineoplastic combined chemotherapy protocols - administration & dosage (20) 20
lymphoma (20) 20
cyclophosphamide - administration & dosage (19) 19
efficacy (19) 19
analysis (18) 18
antibodies, monoclonal - therapeutic use (18) 18
follow-up studies (18) 18
recurrence (18) 18
transplantation (18) 18
antineoplastic agents - therapeutic use (17) 17
vincristine - administration & dosage (17) 17
disease (16) 16
purpura, thrombocytopenic, idiopathic - drug therapy (16) 16
safety (16) 16
cll (15) 15
combined modality therapy (15) 15
doxorubicin - administration & dosage (15) 15
leukemia, lymphocytic, chronic, b-cell - genetics (15) 15
mutation (15) 15
prednisone - administration & dosage (15) 15
salvage therapy (15) 15
splenectomy (15) 15
young adult (15) 15
anti-cd20 monoclonal-antibody (14) 14
antibodies, monoclonal, murine-derived - administration & dosage (14) 14
antineoplastic agents (14) 14
care and treatment (14) 14
chronic lymphocytic leukemia (14) 14
leukemia (14) 14
leukemia, lymphocytic, chronic, b-cell - drug therapy (14) 14
cancer (13) 13
cyclophosphamide (13) 13
fludarabine (13) 13
hemic and lymphatic diseases (13) 13
immunology (13) 13
lymphoma, non-hodgkin - drug therapy (13) 13
survival rate (13) 13
time factors (13) 13
trial (13) 13
chronic lymphocytic-leukemia (12) 12
patients (12) 12
purpura (12) 12
risk factors (12) 12
thrombocytopenia (12) 12
vidarabine - analogs & derivatives (12) 12
antimitotic agents (11) 11
drug administration schedule (11) 11
italy (11) 11
antibodies, monoclonal - administration & dosage (10) 10
antibodies, monoclonal - adverse effects (10) 10
bendamustine (10) 10
multicenter (10) 10
phase-ii (10) 10
prospective studies (10) 10
stem cell transplantation (10) 10
stem cells (10) 10
adults (9) 9
b-cell (9) 9
b-cell lymphoma (9) 9
cell biology (9) 9
cytarabine - administration & dosage (9) 9
hematology, oncology and palliative medicine (9) 9
hepatitis c - complications (9) 9
immune thrombocytopenia (9) 9
italy - epidemiology (9) 9
leukemia, lymphocytic, chronic, b-cell - mortality (9) 9
non-hodgkin's lymphomas (9) 9
risk (9) 9
antineoplastic agents - administration & dosage (8) 8
clinical trials (8) 8
doxorubicin - adverse effects (8) 8
drug therapy (8) 8
expression (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1512 - 1520
Summary Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy... 
Internal Medicine | DEFERRED RADIOTHERAPY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | RESPONSE CRITERIA | EUROPEAN ORGANIZATION | CONSOLIDATING RADIOTHERAPY | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Lymphoma, Non-Hodgkin - radiotherapy | Cranial Irradiation - methods | Central Nervous System Neoplasms - radiotherapy | Adult | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Combined Modality Therapy | Remission Induction | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Cytarabine | Patient outcomes | Central nervous system diseases | Dosage and administration | Lymphomas | Drug therapy, Combination | Methotrexate | Drug therapy | Data analysis | Disease | Monoclonal antibodies | Data collection | Radiation therapy | Patients | Tropical diseases | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2013, Volume 31, Issue 11, pp. 1442 - 1449
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
2009, Studi sul Petrarca / Ente nazionale Francesco Petrarca, ISBN 8884556384, Volume 38, cxlv, 400
Book
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 18, pp. 1733 - 1747
Journal Article
Haematologica, ISSN 0390-6078, 06/2019, Volume 104, Issue 6, pp. 1124 - 1135
The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response rates, making it, nearly 20 years... 
Review
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells
Journal Article
BLOOD, ISSN 0006-4971, 10/2015, Volume 126, Issue 16, pp. 1921 - 1924
Journal Article
European Journal of Internal Medicine, ISSN 0953-6205, 12/2018, Volume 58, pp. 70 - 76
Despite the improvement in understanding its pathogenesis and the introduction of novel treatment options, the management of primary immune thrombocytopenia... 
Splenectomy | Rituximab | Thrombopoietin receptor agonists | ITP | Elderly | ADULT PATIENTS | SINGLE-CENTER | HIGH-DOSE DEXAMETHASONE | LAPAROSCOPIC SPLENECTOMY | MEDICINE, GENERAL & INTERNAL | VENOUS THROMBOEMBOLISM | INTRAVENOUS IMMUNOGLOBULIN | REGULATORY T-CELLS | QUALITY-OF-LIFE | LONG-TERM TREATMENT | Thrombocytopenia | Aged patients | Comorbidity | Thrombosis | Blood clot
Journal Article